Sanofi (NASDAQ:SNY) Lowered to Equal Weight Rating by Barclays

Sanofi (NASDAQ:SNY) was downgraded by research analysts at Barclays from an “overweight” rating to an “equal weight” rating in a research report issued on Tuesday.

SNY has been the topic of a number of other reports. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. HSBC restated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.67.

Sanofi Price Performance

NASDAQ SNY traded up $0.32 during trading hours on Tuesday, reaching $47.83. The company’s stock had a trading volume of 1,715,623 shares, compared to its average volume of 2,098,548. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The firm’s 50-day moving average price is $49.40 and its 200-day moving average price is $48.87. The company has a market capitalization of $117.43 billion, a price-to-earnings ratio of 11.19, a PEG ratio of 1.20 and a beta of 0.45.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. The firm had revenue of $15.46 billion during the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. Sanofi’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.25 earnings per share. On average, equities research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Consulate Inc. acquired a new position in shares of Sanofi in the third quarter valued at about $26,000. Ameritas Advisory Services LLC acquired a new position in Sanofi in the second quarter valued at approximately $28,000. Measured Wealth Private Client Group LLC purchased a new stake in Sanofi during the third quarter worth $29,000. Palisade Asset Management LLC acquired a new position in shares of Sanofi in the third quarter worth about $30,000. Finally, First Horizon Corp purchased a new stake in shares of Sanofi during the 3rd quarter worth about $33,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.